Abstract The main goal of organ-allocation systems is to guarantee equal access to the limited resource of liver grafts for every patient on the waiting list, striking a balance between the ethical principles of equity, utility, benefit, need, and fairness. The European healthcare scenario is very complex, as it is essentially decentralized, and each nation-and region inside the nationoperates with a significant degree of autonomy. Furthermore, the epidemiology of liver diseases and hepatocarcinoma (HCC) differs between European countries and clearly affects indications and priorities. The aims of this review were to analyze the liver-allocation policies for HCC in different European countries. The European area considered for this analysis included five macro-areas or countries with similar liver-sharing and allocation policies: Centro Nazionale Trapianti (CNT) in Italy; Eurotransplant (Germany, the Netherlands, Belgium,
Introduction
The first attempts at liver transplantation (LT) in patients with hepatocarcinoma (HCC) were reported almost 50 years ago in early 1967 [1] ; these cases resulted in early tumor recurrence and death within a few months of LT. Because of these negative outcomes, HCC was widely recognized as a contraindication for LT [2] until the mid-1990s, when the Milan group, headed by Vincenzo Mazzaferro, published his pioneering results showing that the post-transplant survival of patients with early HCC was similar to that of patients without cancer [3] . Since then, LT has become the standard of care worldwide for early HCC in patients with cirrhosis, and the so-called Milan criteria are now universally accepted as the benchmark for patient selection for LT in HCC. When discussing LT for HCC, two aspects are important: first, the indication for transplant (Milan criteria, San Francisco criteria, Up-to-seven criteria, etc.); second, how to prioritize one patient with HCC over another and in terms of non-oncologic indications.
A recent analysis of European Liver Transplant Registry (ELTR) data highlighted that progressively more LTs have been performed for HCC over the last decade [4] , a trend also confirmed in the US United Network for Organ Sharing (UNOS) database [5] . The higher number of patients with HCC on transplant waiting lists created a new scenario in which those patients compete with patients with end-stage liver disease (ESLD) for graft allocation. The imbalance between the increasing number of candidates for LT and the limited pool of donors means allocation and prioritization policies that ensure fair and equal access are crucial.
The goal of allocation systems is to guarantee equal access to the limited number of liver grafts for every patient on the waiting list (i.e., cirrhotic patients with end-stage liver failure [ESLF] , cirrhotic patients with HCC, cholangiocarcinoma [CCA] , or metabolic and rare disorders) while finding a balance between the ethical principles equity, utility, benefit, and fairness. In 2002, UNOS adopted the Model for End-stage Liver Disease (MELD) scoring system for liver allocation to reduce list mortality and consequent dropout. The more recent Na-MELD score is based on objective measures such as total bilirubin and creatinine levels, international normalized ratio (INR), and sodium concentration. The MELD score provides accurate information about short-term mortality. However, in a number of clinical conditions, the risk cannot be accurately quantified using the MELD score. These 'MELD exceptions' include a diverse array of conditions in addition to CCA and HCC.
Indeed, most patients with HCC present with low MELD scores, and their mortality risk is determined by progression of the neoplasm, rather than by further decrease in liver function. To overcome this structural problem and reduce waiting list dropout, UNOS recognized HCC as a MELD exception and allocated additional MELD points to patients with HCC, thereby raising their priority level. This resulted in a sizable increase in the number of patients transplanted for HCC. UNOS has adjusted this priority a number of times as it was felt to favor patients with HCC over those listed for ESLD.
In Europe, no central organization coordinates liver procurement and allocation at a pan-European level (similar to the UNOS/Organ Procurement and Transplantation Network
[OPTN] in the USA); rather, multiple organ-exchange organizations with different rules and systems operate in different countries and geographical areas. The aim of this review is to analyze the liver-allocation policies for HCC among these organizations.
Principles of Liver-Allocation Policies
The European areas considered for this analysis included five macro-areas or countries with a similar liver-sharing and allocation policy (Table 1) .
The allocation policy for livers from deceased donors is dominated by two primary principles: urgency and utility. The principle of urgency is based on the clinical severity of the disease and the prognosis. As the number of patients waiting for LT is higher than the number of available organs, every liver transplant candidate is exposed to a sizable risk of death or dropout from the waiting list. The urgency policy calls 'the sickest first', prioritizing patients to decrease their risk of dropout/death. Centers who adopt an urgency-based policy consider variables such as MELD score, time from listing, and size/numbers of nodules to assign additional MELD points to reduce the risk of patient dropout [6] [7] [8] . Leading models based on the urgency principle for HCC are the HCC-MELD, the deMELD, and the new de-MELD [9] . This policy entails the reassessment of risk based on tumor response to pre-transplant locoregional treatments. However, in urgency-based models, the outcome of transplantation weighs less than the need to provide possibly life-saving treatment. Unfortunately, the sickest patient does not always represent the ideal patient for transplant because of the higher transplant-related mortality compared with patients at an earlier stage of disease.
Conversely, in utility-based models, the best candidate for transplantation is the patient who may gain the most life-years from transplantation. Therefore, by maximizing the utility of allocation, this model evaluates the survival benefit that would be obtained from the transplant (number of years gained) compared with those provided by alternative treatments. This model takes into account both pre-and post-transplant outcomes, including the results of alternative treatments, to Sweden, Norway, Finland, Denmark, and Iceland achieve the best survival benefit from the transplant. Therefore, this model reduces the priority of patients for whom the survival gain is lower compared with alternative treatments [10] [11] [12] . The limits of this model are essentially related to the outliers. The ideal survival benefit should take into account all factors that may impair patient survival before and after transplantation, not only variables related to the underlying disease but also those related to patient baseline characteristics and lifestyle. Although appealing from a theoretical viewpoint, this model may be less effective when applied to the entire cohort of patients waiting for transplant. Indeed, in practice, it is extremely difficult to factor in all variables affecting survival in a model that accurately fits all needs. Furthermore, the leading studies on the benefit model were constructed on the basis of 5-year survival rather than on the 10-year horizon; this may limit real appreciation of the benefit of the transplant in comparison with alternative treatments. Alongside the principles of urgency and benefit, each of the five European areas adopts either a center-oriented or a patient-oriented policy. A center-oriented policy means the organ-procurement agency assigns the organ to a specific center based on geographic and/or other rotational criteria, and that center then matches the donor with an appropriate recipient from the waiting list at the center. On the other hand, a patient-oriented policy means livers are allocated based on the patient's absolute priority on a common shared list regardless of geographic distribution or center rotation. The UNOS system is a clear example of a patient-oriented policy.
In Europe, several policies lie between the two extremes, usually mitigating the center-based policy with nation-or region-wide urgent priority for patients with a high MELD score.
Leading European Policies
The following paragraphs report the allocation and prioritization criteria adopted in the five leading European organsharing systems (Table 1) .
Centro Nazionale Trapianti -Italy Centro Nazionale Trapianti (CNT) coordinates organ allocation in Italy. Transplant priorities are allocated following the Milan criteria or the up-to-seven criteria. Liver allocation is center oriented, and patients are prioritized according to MELD score. There is no central policy concerning liver allocation for HCC: organs are allocated independently within each center's waiting list. Over recent years, the Bologna group has reported a preferential use of elderly grafts for patients with HCC and low MELD scores [13] and described its internal model of HCC prioritization according to tumor stage and waiting time [14] . The Padua group has recently developed and validated a new allocation model for prioritizing both patients with and without HCC according to the common endpoint of survival benefit, the so-called HCC-MELD. This model has been computed according to liver function and alpha-fetoprotein (AFP) level and calibrated to survival benefit of patients without HCC expressed by MELD score [15••] Table 2 .
Eurotransplant -Germany, the Netherlands, Belgium, Luxembourg, Austria, Hungary, Slovenia, and Croatia Eurotransplant (ET) covers all of central Europe. Organ allocation is patient oriented in four countries within the ET region (Germany, Belgium, the Netherlands, Luxembourg) and center oriented in the other four (Austria, Hungary, Slovenia, and Croatia). Patients are generally selected according to Milan criteria: patients eligible for LT are those presenting with a single nodule <5 cm or up to three nodules >3 cm or patients downstaged within such criteria. Patients are prioritized according to MELD score. The allocation protocol is well defined inside the ET Liver Allocation System (ELAS) and is based on medical criteria such as blood group, weight, size, and recipient MELD score. HCC is considered a MELD exception: patients with HCC receive a starting MELD score equivalent to a 15 % probability of death within 3 months at the time of listing (except in the Netherlands, where such an initial score equals a 10 % 3-month mortality risk) and a +10 % MELD-equivalent bonus every 3 months provided they remain eligible for LT (i.e., stable disease within Milan criteria) [16] . Etablissement français des Greffes -France The Etablissement français des Greffes (EfG) coordinates the entire liver procurement and allocation process in France.
Patients are selected according to Milan criteria: patients eligible for LT are those presenting with a single nodule <5 cm or up to three nodules >3 cm or patients downstaged within such criteria. Liver allocation is patient oriented. The French Liver Allocation System (FLAS) was implemented in 2007 and considers severity of cirrhosis (evaluated with MELD score) as well as other frequent conditions (e.g., HCC and the need for retransplantation) not necessarily associated with high MELD scores: specific formulas have been computed for each indication for LT according to a national retrospective analysis by the Agency of Biomedicine. Points are given to patients with HCC in addition to the MELD score, which is usually not very high. The number of points depends on the MELD score (the higher the MELD score, the higher the point maximum); the maximum point total with the lowest MELD score of 6 is 360 for patients with T1 HCC and 450 for those with T2 HCC. These points are progressively acquired by patients on the waiting list, and the progression rate varies with the HCC stage. For patients with T1 HCC who have a low and stable score and do not progress on the waiting list in the first months, the slope increases until 12-18 months; this ideally leads to access to a graft within a year. In contrast, patients with T2 HCC must obtain access faster. No initial delay is considered, and points are continuously given from the time of listing until the point maximum is obtained; this theoretically leads to access to a liver graft after 6 months. Again, patients with high MELD scores and HCC obtain access to transplantation more rapidly than patients with low MELD scores [19] .
UK National Health Service Blood and Transplant -UK, Ireland The UK National Health Service Blood and Transplant (NHSBT) provides essential support for organ procurement via the new National Organ Retrieval Service introduced in the UK on 1 April 2010. Liver allocation in the UK is center oriented; patients on the waiting list are prioritized via application of UKELD (a modified MELD including Na as a variable) [20] . Patients are selected according to Milan criteria: patients eligible for LT are those presenting with a single nodule <5 cm or up to three nodules >3 cm or patients downstaged within such criteria. The UK does not award priority points for patients with HCC awaiting LT; the outcomes of this policy in terms of waiting list dropout are unknown [21] . The allocation priority at each center is decided by transplant surgeons and physicians on call. National guidelines currently do not specify which patient to select when a liver suitable for more than one recipient is offered. A significant number of factors influence the decision of the transplant professional, including quality and size of the donated liver, blood group, health condition of the potential recipient, and logistics of pressure on intensive care unit beds and on staff. The decision as to whether a liver should be transplanted into an individual should consider both recipient and donor factors.
Scandiatransplant (Sweden, Norway, Finland, Denmark, and Iceland) Scandiatransplant is a collaboration of all organ transplant centers in the Nordic countries: Sweden, Norway, Finland, and Denmark. Liver allocation is center oriented. Patients are selected according to Milan criteria: patients eligible for LT are those presenting with a single nodule <5 cm or up to three nodules >3 cm or patients downstaged within such criteria. The Nordic countries have generally had a favorable organ donation rate with short waiting lists, therefore the MELD score is not used to prioritize patients for LT. However, it is sometimes used locally at individual centers to help match an available organ with the patient in greatest need [22] . Center-oriented allocation is used, and each transplant center has its own waiting list and the right to transplant livers procured from a defined geographical area. MELD and/ or Child-Turcotte-Pugh scores are usually used in conjunction with clinical (e.g., medical urgency, recipient size, recipient age) and nonclinical (e.g., waiting time) parameters to select patients for LT.
Conclusions
A common organ-allocation policy among European countries is still lacking. Most European organizations adopt a center-oriented policy, but no data are available on how the organs are subsequently assigned to actual patients in the waiting list. Unlike patient-oriented systems, each center establishes its own criteria to prioritize patients in the waiting list. Interestingly, leading studies on European patient cohorts report favorable long-term survival and intention-to-treat survival, regardless of the organ-allocation policy [23, 24] . It is possible that these differences in transplant policies between the European areas may actually play a favorable role, by enabling flexible adaption to differing local circumstances, including prevalence of HCC and ESLD, donation rates, and pool. Patient placement onto the transplant list is obviously influenced by the indication/allocation policies; unfortunately, no information is available for patients who are not listed. Thus, despite favorable general survival rates, we have no reliable data to enable us to analyze the ability of the organ-allocation policy to satisfy the need for LT, including access and the crucial ethical principles of equity and transparency [3-14, 15••, 16-18] .
Over the past decade, UNOS has used an urgency-based patient-oriented system, which has then been applied by individual European centers. The system was partly utility based, as only patients who met Milan criteria (i.e., with better a priori prognosis) were listed. Patients with HCC received a modified and progressive MELD score intended to reflect the time-based dropout risk during their waiting time for a given oncologic stage (T1 or T2). Additional points were awarded independently for response to intermediate treatments. This system created a greater likelihood of transplant for patients with HCC than for patients with non-neoplastic diseases, creating a disadvantage for the latter [12-14, 15••, 16-19] .
The survival-benefit approach is supposed to be more uniform and predictable. Thus, several authors have proposed prioritization models that include variables with a strong impact on the individual patient risk of dropout and posttransplant outcome, such as AFP and the MELD score itself. Models based on survival benefit should promote an ideal balance between the principles of urgency and utility. Vitale et al. [15••] proposed a unique method (HCC-MELD) to equalize priorities for patients with and without HCC by converging on the common goal of maximizing survival benefit. The HCC-MELD is an upward continuous score that assigns a survival benefit based on variables defining the years of life a patient earns with the transplant compared with alternative treatments to transplant. This model does not neglect the principle of utility as it also poses a minimum threshold of posttransplant survival of 50 % at 5 years, which therefore excludes patients without that expected prognosis. The performance of this model is awaiting validation [15••] .
Mazzaferro [25••] recently published a manuscript intended to square the circle in the arena of transplant indication and graft allocation in patients with HCC. The proposed model applies only to Barcelona Clinic Liver Cancer (BCLC) level A and B patients, as those with vascular invasion, extrahepatic metastases, or other contraindications are excluded from transplant, and patients with high MELD scores would be prioritized according to liver function. Patients who met the inclusion criteria were defined as having a 'transplantable tumor' (TT). Eight groups of patients affected by TTs and otherwise low MELD cirrhosis received priority based on tumor characteristics and on the modality and efficacy of alternative treatments. The lowest priority is assigned to patients who have previously received radical treatment for HCC and have no viable tumor in the liver at the time of listing (TT0 c ) or last follow-up. Conversely, patients with recurrent HCC after initial downstaging or after resection performed less than 2 years before the recurrence diagnosis (TT DR ) receive the highest priority. Between these two stages, the author considered six more classes of priority from the lowest to the highest: patients with no viable tumor after effective locoregional chemotherapy or radiotherapy embolization (TT0 L ), patients with single active HCC <2 cm (TT1), patients effective downstadiated with HCC that was not transplantable at the time of tumor diagnosis (TT NT ), patients with HCC > T1 or recurrent HCC after resection perfumed more than 2 years before tumor recurrence diagnosis (TT FR ); patients not amenable to alternative HCC treatments because of ascites, but tumor compatible with transplant criteria (TT UT ); patients with incomplete response to the bridging loco-regional treatment and viable tumor into the liver (TT PR ) [25••, 26] .
This model aims to overcome the limits of previous models that considered tumor size and number the leading risk factors for assessing the risk of dropout from waiting lists and/or a proxy of transplantation outcome. Only recently have a few authors begun to assess the actual weight of tumor response to the bridging loco-regional treatment as a tool to re-assess priority for candidate patients [26, 27] . The outcomes of patients at the same tumor stage in terms of size and number of nodules may differ because of tumor biology and response to treatment. Response to locoregional treatment performed while on the waiting list defines the risk of dropout [26] . The model proposed by Mazzaferro appears able to contemplate the different scenarios of HCC presentation and management and in setting priorities. By assigning higher priority to those at higher risk of progression after alternative treatment, it makes the best use of the transplant resource (population utility) while still prioritizing the sickest. This model is awaiting validation, and further work is needed to balance urgency/utility with the goal of achieving the best benefit in patient survival.
In conclusion, the method of liver allocation for patients waiting for LT in Europe differs by area and sometimes by center. Regardless, long-term survival rates for of patients waiting for transplant for HCC are acceptable and comparable to those reported in the UNOS register. Physicians should continue to explore alternative allocation policies with the aim of continuously improving equity and transparency and of improving the effectiveness of LT. Future policies should take into account two parameters: the impact of AFP in candidates and tumor response to loco-regional treatments received while waiting for LT. The general global scenario is changing rapidly because of the impact of the hepatitis C cure, which will require physicians to re-assess global allocation policies and indications for LT in the near future.
